A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC) 1 . Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types 2 . However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade 3-5 , motivating a search for targeted therapies that overcome this resistance. Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumour immune evasion 6 . The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer 7-9 . Mouse models of prostate cancer show that MDSCs (CD11b + Gr1 + ) promote tumour initiation 10 and progression 11 . These observations prompted us to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function. Here we develop a novel chimaeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting. Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy. Targeted therapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumour activities. Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy. Mechanistically, combination therapy efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDSCpromoting cytokines secreted by prostate cancer cells. These observations illuminate a clinical path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.
novel non-germline mCRPC model in a C57BL/6 background through first establishing JH61 and JH58 mouse embryonic stem cell (mES cell) clones (Extended Data Fig. 1b-d ) derived from the following genotypes: PB-Cre + Pten L/L p53 L/L Smad4 L/L mTmG L/+ LSL-LUC L/+ (CPPSML), which exhibited age-dependent green fluorescent protein (GFP + )LUC + PCa development (Fig. 1a ). In high-percentage chimaeras derived from JH61 or JH58 mES cells (Extended Data Table 1a ), 50% of mice (4 out of 8 necropsied) developed GFP + cancer cells at 3 months of age and showed dissemination of cancer cells to draining lymph nodes and lung (Extended Data Fig. 1e, f) . In prostate, GFP + areas corresponded to CK8 + /CK5 + adenocarcinoma (Extended Data Fig. 1g, h) . Importantly, we observed a fourfold increase in the rate by which PCa-bearing mice can be generated using chimaeric modelling (Extended Data Fig. 1a ).
To study combination therapy targeting mCRPC, we first employed the PB-Cre + Pten L/L p53 L/L Smad4 L/L germline model and demonstrated that an androgen deprivation therapy protocol (castration followed by enzalutamide-admixed diet) generated a significant, albeit transient, survival benefit (Extended Data Fig. 2a ). Next, CPPSML chimaeras were subjected to the same androgen deprivation therapy to induce CRPC. To ensure consistency, MRI was used to assign chimaeras with prostate tumour volumes over 150 mm 3 before 18 weeks of age: 86 out of 107 (80.4%) chimaeras met this criterion ( Fig. 1b and Extended Data Fig. 2b ). We validated emergence of CRPC in CPPSML chimaeras by comparing the response of size-matched primary prostate tumours with androgen deprivation therapy in three cohorts: the chimaeras, CPPSML mice through breeding, and castration-sensitive PB-Cre + Pten L/L mice (Fig. 1c ). All treated chimaeras succumbed to primary CRPC, with metastases in lymph nodes and micrometastases in lungs (Extended Data Fig. 2c ). Thus, the CPPSML chimaera models provide a speedy platform to test multiple therapies on mCRPC. Next, mCRPC-bearing chimaera mice were assigned to therapeutic trials. The targeted agents were selected on the basis of (1) strong activity in preclinical PCa models, (2) initial activity and safety in early phase trials but failure to improve overall survival in phase III trials of mCRPC, and/or (3) purported immunomodulatory activities and thus the potential to enhance or negate immune checkpoint blockade (ICB). The agents selected were the tyrosine kinase inhibitors dasatinib (Dasa) 15 and cabozantinib (Cabo) 16 , and the phosphoinositide 3-kinase (PI3K)/mTOR dual inhibitor BEZ235 (BEZ) 17, 18 . Of relevance to this study, previous evidence suggests that PI3K pathway activation in both cancer cells and cancer-associated myeloid cells can mediate immunosuppression [19] [20] [21] [22] [23] and that BEZ exhibits minimal inhibitory activity on mouse T cells 24 . For ICB, we used a cocktail of anti-CTLA4 and anti-PD1 antibodies to maximize the blockade of checkpoint pathways, a regimen in line with a clinical treatment protocol currently being tested in a phase II trial for mCRPC (NCT02601014). CPPSML chimaeras (generated from JH61) with induced and MRI-documented mCRPC were randomized to receive single or combination treatments for 4 weeks before endpoint analysis (Extended Data Fig. 2d ). While all targeted agent monotherapies or dual ICB cocktail had minimal impact on prostate tumour mass, the combination of Cabo + ICB or BEZ + ICB showed potent synergistic efficacy in targeting primary and metastatic PCa growth (Fig. 1d-f and Extended Data Fig. 2e ). In contrast, ICB alone or Dasa + ICB showed minimal impact on primary or metastatic disease burden, although ICB alone resulted in significant reduction of lymph node metastasis and lung micrometastasis ( Fig. 1d-f and Extended Data Fig. 2e ). In a corroborating study with chimaeras derived from JH58, Cabo + ICB also generated significant efficacy in the mCRPC setting (Extended Data Fig. 3a -c). At necropsy, Cabo + ICB-and BEZ + ICB-treated CRPC mice showed minimal residual tumour cells in the prostate (Extended Data Fig. 2e ), reduced proliferation, and pronounced apoptosis (Extended Data Fig. 3d-g) .
We catalogued the constellation of intratumoural immunocytes by time of flight mass cytometry (CyTOF) 11 in the various treatment arms as part of end-point analyses. Continued Dasa, but not Cabo or BEZ, treatment was associated with a significant reduction of . Red bar, mean. * P < 0.05, * * P < 0.01, * * * P < 0.001, Mann-Whitney U-test. c, d, In vitro sensitivity to Cabo (c) and BEZ (d) by MDSCs, CD8 + T cells, and GFP + PCa cells isolated from CRPC in CPPSML mice with IC 50 indicated (n = 3, biological replicates). e, T-cell proliferation (prolif.) assay when co-cultured 1:1 with MDSCs isolated from control or drug-treated CRPC. High and low proliferation was defined as T-cell division ≥ 3 and ≤ 2, respectively (n ≥ 4, biological replicates). f, g, Drug effect on CD8 + (f) and CD4 + (g) T-cell proliferation assay. High, moderate, and no proliferation was defined as T-cell division ≥ 3, ≤ 2, and 0, respectively (n = 3, biological replicates). h, i, Drug effect on IFNγ secretion (by CD8 + T cells) and IL-2 secretion (by CD4 + T cells) in the assay in f and g measured by enzyme-linked immunosorbent assay (ELISA) (n = 3, biological replicates). In c, d, h, and i, data represent mean ± s.d. Fig. 4a ), suggesting that the small impact of Dasa + ICB may reflect depletion of T cells in the tumour microenvironment. This finding is consistent with reported Dasa inhibition of TCR-mediated signal transduction and proliferation 25 . CPPSML PCa tumours predominantly contain granulocytic MDSCs (Gr-MDSCs, CD11b + Gr1 + Ly6G + Ly6C low ) (Extended Data Fig. 4b ). Either Cabo or BEZ treatment resulted in a significant reduction of Gr-MDSCs, while ICB alone had no impact ( Fig. 2a ). However, ICB significantly increased the ratio of CD8 + to regulatory T cells (T reg ) ( Fig. 2b) , a defining feature for ICB-based therapies. Cabo + ICB and BEZ + ICB further elevated CD8 + /T reg ratios ( Fig. 2b ). MDSC depletion with anti-Gr1 neutralizing antibody 11 sensitized CRPC in CPPSML to ICB (Extended Data Fig. 4c ), arguing that MDSCs mediate de novo resistance to ICB and suggesting that Cabo or BEZ enhances ICB through diminishing MDSCs.
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tumour-infiltrating T cells (Extended Data
To explore the impact of these agents on cells in the tumour microenvironment, in vitro viability assays were performed to audit Cabo, BEZ, and Dasa activity on MDSCs, CD8 + T cells, and GFP + PCa cells collected from CRPC in CPPSML. Relative to CD8 + T cells and GFP + PCa cells, MDSCs displayed a significantly higher sensitivity to Cabo and BEZ, but not to Dasa (Fig. 2c, d and Extended Data Fig. 5a ). Similar half-maximum inhibitory concentration (IC 50 ) results were obtained when MDSCs were assayed in medium supplemented with 10 ng ml −1 granulocyte-macrophage colony-stimulating factor (GM-CSF) (Extended Data Fig. 5b ) or in medium supplemented with GM-CSF and pre-conditioned for 12 h by PCa cell lines established from the CPPSML model (Extended Data Fig. 5c ). Moreover, Cabo or BEZ treatment alleviated the suppressive activity of intratumoural MDSCs on CD4 + and CD8 + T-cell proliferation ( Fig. 2e and Extended Data Fig. 5d ). On the other hand, CD8 + and CD4 + T-cell in vitro proliferation was only moderately suppressed by Cabo or BEZ, yet completely blocked by Dasa ( Fig. 2f , g and Extended Data Fig. 5e ). Equivalent drug effects on interferon (IFN)-γ and interleukin-2 (IL-2) production by T cells were observed ( Fig. 2h , i). In summary, Cabo and BEZ elicited a pronounced effect on the infiltration and activity of MDSCs.
Next, phospho-receptor tyrosine kinase (phospho-RTK) antibody arrays were used to assess the effect of Cabo and BEZ on the phospho-RTK signalling in treated CPPSML tumours (Extended Data Fig. 6a ), revealing Cabo-induced downregulation of pEGFR, pErbB2, pErbB3, pAxl, and pPDGFRα , and partial downregulation of pEGFR, pErbB3, and pAxl through indirect effect by BEZ ( Fig. 3a) . We further observed that Cabo or BEZ also reduced phosphorylated MET (pMET) and phosphorylated vascular endothelial growth factor receptor 2 (pVEGFR2) levels, and significantly suppressed PI3K-Akt-mTOR signalling in CPPSML tumours (Fig. 3b ). Correspondingly, Cabo or BEZ decreased pS6 signalling in intratumoural Gr1 + MDSCs in the CPPSML tumour microenvironment (Extended Data Fig. 6b , c). These findings raised the possibility that Cabo and BEZ compromise MDSCs through inhibition of PI3K signalling. To test this hypothesis, we sought to rescue the viability of Cabo-or BEZ-treated MDSCs with 
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enforced downstream activation of signalling surrogates. Specifically, MDSCs were isolated from the induced CRPC in CPPSML and co-transfected with recombinant active ERK2 and p70S6K proteins ( Fig. 3c ). Transfected MDSCs showed improved survival under Cabo or BEZ treatment ( Fig. 3d, e ). Similar results were obtained when the assay was performed in enhanced medium (Extended Data Fig. 6d , e). These results reinforce the view that Cabo and BEZ exert an impact on the PCa tumour microenvironment in part via selective depletion of MDSCs. As cytokine signalling plays a pivotal role in the recruitment and activation of MDSCs 6 , we further explored the impact of combination treatment on cytokine production in primary CRPC. Cytokine arrays revealed that several key cytokines involved in regulating recruitment and activity of immunosuppressive myeloid cells, including CCL5, CCL12, CD40, and HGF, were reduced by Cabo + ICB or BEZ + ICB treatment. These treatments were also associated with increased IL-1ra, CD142, and VEGF ( Fig. 3f and Extended Data Fig. 7a ). IL-1ra may contribute to reduced MDSC infiltration 26 . We confirmed that recombinant IL-1ra inhibited IL-1 induced chemoattraction of MDSCs, and this effect was blocked by IL-1ra neutralizing antibody ( Fig. 3g) . Notably, the cytokine changes were significantly less pronounced in Dasa + ICB treatment (Extended Data Fig. 7b ). Noting that cytokine production by cancer cells may influence the functional status of myeloid cells, we cultured MDSCs isolated from CRPC with conditioned medium from the CPPSML PCa cell lines (Extended Data Fig. 7c ) and showed upregulated expression of genes responsible for MDSC-induced immune suppression, including Arg1, Cybb, Ncf1, and Ncf4 (refs 6, 11) ( Fig. 3h ). Critically, the expression induction was largely abolished if the PCa cells were pre-treated with Cabo or BEZ before conditioned medium was collected ( Fig. 3i ), whereas direct treatment of MDSCs with Cabo or BEZ caused insignificant expression changes (data not shown), suggesting that certain cytokines in the conditioned medium may drive the gene upregulation. Through cytokine array (Extended Data Fig. 7d ), we identified ten cytokines significantly downregulated in the conditioned medium of PCa cells pre-treated with Cabo or BEZ ( Fig. 3j ), among which CCL5 was also identified as a downregulated cytokine in Cabo + ICB-and BEZ + ICB-treated CRPC ( Fig. 3f ). When MDSCs isolated from CRPC tumours were treated with each of the ten cytokines in the presence of Cabo or BEZ, significant upregulation of Arg1, Cybb, Ncf1, and Ncf4 was observed with most of the cytokines tested (Extended Data Fig. 7e ). Therefore, PCa cells are capable of driving immunosuppression-related gene expression in MDSCs through secretion of multiple cytokines, and this paracrine signalling is impaired by Cabo or BEZ treatment.
BEZ targets multiple p110 isoforms. To test whether isoform-specific PI3K inhibitors would generate a comparable level of synergistic advantage when combined with ICB, we tested PI-3065 (p110δselective inhibitor 27 ) and GSK2636771 (p110β -selective inhibitor 28 ). Moreover, given the critical role of Cxcr2 in MDSC recruitment 10, 11 and the downregulation of Cxcr2 ligands Cxcl1 and Cxcl2 in the conditioned medium of PCa cells treated with Cabo and BEZ ( Fig. 3j) , we also tested a novel clinical-stage Cxcr1/2 inhibitor SX-682 (Extended Data Fig. 7f , g) as monotherapy or in combination with ICB in the CPPSML model. Mild to moderate effects of PI-3065, GSK2636771, or SX-682 as single agents on CRPC progression were observed, yet combination with ICB produced strong efficacy ( Fig. 4a, b ). To give further credential to our model and assess the pattern of MDSCs in human PCa, a 32-antibody CyTOF panel was developed (Extended Data Table 1b ) and used to analyse 12 fresh fine-needle biopsy samples from ten treatment-naive PCa tumours (Extended Data  Table 1c ). Analysis with SPADE software displayed the heterogeneous immune cell populations (Extended Data Fig. 8 ). Results showed the prominence of Gr-MDSCs relative to Mo-MDSCs, with the latter occupying no nodes in the SPADE tree ( Fig. 4c ). Total T-cell load across LETTER RESEARCH the samples varied considerably (Fig. 4d ), yet the frequency of CD8 + T cells correlated inversely with the frequency of Gr-MDSCs (Fig. 4e ), a pattern consistent with the conservation of antagonistic activity of Gr-MDSCs on CD8 + T cells in human PCa.
Here, by using a chimaeric model of mCRPC, we have shown that ICB alone is insufficient to generate an effective response, but a combination of ICB with drugs that inactivate MDSCs demonstrates superior synergistic efficacy against de novo resistance to ICB (Extended Data Fig. 9 ). The differential sensitivity of MDSCs and CD8 + T cells to Cabo, BEZ, and possibly other phosphokinase inhibitors should provide an avenue for optimizing the dose and schedule for effective silencing of MDSCs while simultaneously sparing cytotoxic T lymphocytes to attack cancer cells. As with all preclinical model systems and human clinical pathological correlations, prospective clinical trials will be needed to substantiate the hypotheses of our work. Future studies should explore the combination therapy in the context of both established mCRPC and newly diagnosed PCa together with selective anti-androgens to achieve durable clinical response in this major cancer of men.
METHODS
Ethics statement and transgenic mice. All animal work performed in this study was approved by The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee. All animals were maintained in pathogen-free conditions and cared for in accordance with the International Association for Assessment and Accreditation of Laboratory Animal Care policies and certification. All surgeries were performed with isoflurane anaesthesia. Analgesic was administered after surgery along with temperature-controlled post-surgical monitoring to minimize suffering. PB-Cre + Pten L/L p53 L/L Smad4 L/L mice were described previously 13 . Mice were crossed to Rosa26-Lox-tdTomato-Lox-EGFP (mTmG) allele 29 (The Jackson Laboratory, 007676) and Rosa26-pCAGGs-LSLluciferase (LSL-LUC) allele (MMRRC, 01XAC), both of which were already congenic to C57BL/6, and further backcrossed to C57BL/6 background for four generations. Mice were then intercrossed to obtain 'CPPSML' males with homozygous status of Pten, p53, and Smad4, heterozygous status of mTmG and LSL-LUC, and hemizygous status of PB-Cre. To calculate the expected frequency of pups to develop prostate tumours, several factors were included: only males were considered; PB-Cre had to be transmitted from males to the next generation owing to the non-specific expression in oocytes 30 , thus only half of the litter was Cre + ; moreover, to circumvent paternal infertility caused by the diseased prostate, the key loxP-flanked tumour suppressor alleles (for example, Pten/p53 (ref. 31 ), or Pten/Smad4 (ref. 14)) that were needed for aggressive PCa were maintained as heterozygous state for the Pten loxP allele in the males for continued fertility (p53 or Smad4 could be homozygous) 13, 14 , thus only half of the litter was homozygous for all tumour suppressor alleles. Mice with spontaneous prostate tumours were euthanized at designated time points for tumour collection. Owing to the internal status of the tumours, we used signs of lethargy, reduced mobility, and morbidity, rather than maximal tumour size, as a protocol-enforced end point. All components were prepared and filter sterilized before use. The culture dish containing the isolated blastocysts was left undisturbed in a water-jacketed coppershelved incubator at 37 °C and 5% CO 2 . Six days after isolation and culture, mES cell outgrowths were visible and individually picked using an Oxford P20 pipette with sterile 100 μ l round gel filtered tips (USA Scientific, 1022-0810). Each outgrowth was transferred to a well of a sterile 96-well U-bottomed dish containing 15 μ l sterile PBS. Forty-five microlitres of 0.25% trypsin-EDTA (Invitrogen, 25200-056) was added to each well. After incubation for 4 min at 37 °C with 5% CO 2 , each well was quenched with 300 μ l of mES cell media containing fetal bovine serum (FBS) and pipetted up and down six to eight times using a multichannel pipette with sterile elongated tips, to generate cell clumps. Individual cell clump populations were transferred to corresponding wells of a 48-well plate containing 14-16 h pre-plated mouse embryonic fibroblasts in pre-equilibrated mES cell culture medium. Once the wells reached ~ 80% confluency they were split to triplicate plates for expansion in culture, freezing, and DNA isolation. Generated mES cell lines were genotyped and clones with the genotype PB-Cre + Pten L/L p53 L/L Smad4 L/L mTmG L/+ LSL-LUC L/+ (CPPSML) were selected. They were confirmed to be mycoplasma negative, and screened for the presence of the Y chromosome. Chromosome spreads were prepared and observed for abnormalities. Background characterization was performed by single-nucleotide polymorphism analysis. Chimaera cohort development. Derived mES cell lines JH58 and JH61 were geno typed as PB-Cre + Pten L/L p53 L/L Smad4 L/L mTmG L/+ LSL-LUC L/+ (CPPSML) and confirmed to contain the Y chromosome. Chimaera cohorts were produced by blastocyst microinjection of the mES cells into C57BL/6NTac-Tyr tm1Arte (Taconic, 11971) then followed by uterine implantation into pseudo-pregnant CD-1 (Charles River, 022) or Swiss Webster (Taconic, SW-F) female mice.
Specifically, cell lines were cultured to roughly 80% confluence on inactivated mouse embryonic fibroblasts in wells of a 24-well plate in mES cell culture media described above. Cells cultured for injection were split 11-16 h before preparation for microinjection. Cells were removed from incubation, washed with sterile PBS, and trypsinized with 0.25% trypsin-EDTA. Trypsin was quenched with mES cell culture media containing FBS and the cell culture plate was returned to incubation for 45 min to allow the larger mouse embryonic fibroblasts to re-attach to the bottom of the cell culture well. After that incubation, the desired mES cells were collected and transferred to a 15 ml conical tube. The suspension was brought up to 5 ml with mES cell culture media, gently pipetted up and down to mix, and then spun down at 4 °C and 800 r.p.m. for 4 min. All except 100-200 μ l of media was aspirated from the tube. The bottom of the conical tube was tapped externally to break up the cell pellet and the tube was placed on ice for microinjection use.
C57BL/6NTac-Tyr tm1Arte female mice that had achieved successful strainmatched mating after superovulation via timed gonadotropin administration were used as donors for 3.5 day blastocysts. Blastocysts were collected by uterine flush and cultured in M16 medium (Millipore, MR-016-D) overlaid with embryo-tested oil in a 35 mm culture dish at 37 °C with 5% CO 2 . Blastocysts were each micromanipulated to insert roughly 12 individual mES cells into its blastocoel. Injected blastocysts were then implanted into the uteri of pseudo-pregnant females. Each pseudo-pregnant female received up to 14 micromanipulated blastocysts (up to seven blastocysts per uterine horn). Chimaeras were verified with prostate tumour formation by MRI and assigned into preclinical studies through randomization which maximized the chance that male mice housed in the same cage received different drugs. Blinding was not applied, because allocation required investigators to assess mouse prostate tumour size with MRI before randomization. Pups were excluded from tumour analysis if they died without significant sign of tumour formation. Single-nucleotide polymorphism analysis. Single-nucleotide polymorphism analysis was performed in the Genetic Services core at MD Anderson Cancer Center. For background characterization of the JH61 ES cell line, 80 microsatellite (simple sequence length polymorphism, SSLP) markers, polymorphic between FVB/N and 129S6 inbred strains, and evenly distributed along the genome (that is, genome scan), were used as described 32 . To analyse the MHC region on mouse chromosome 17, an extra 15 polymorphic SSLPs flanking the H2 complex were added. The results (allelotype) obtained for the SSLP in the H2 region were confirmed by means of H2 polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotype as described 33 . Non-invasive mouse and ex vivo imaging. For MRI imaging with Bruker ICON, the animals were anaesthetized with 1-3% isoflurane and placed on the ICON animal bed. The MRI coil was secured into position over the animal and the entire bed assembly was placed into the Bruker ICON 1T MRI bore. Rapid acquisition with relaxation enhancement (RARE) T2-weighted images were acquired in both the coronal and axial planes. After the imaging was completed, the animals were allowed to recover under a heating lamp until fully conscious. MRI images were loaded into ImageJ to manually demarcate the contour of the prostate and calculate the total volume. Bioluminescence imaging with IVIS Spectrum was performed as previously described 34 . Fluorescence imaging of dissected prostate tumours, the pair of draining lymph nodes, and lung was performed with a Leica M165FC fluorescence stereomicroscope. Lymph node metastasis score was assigned as 0 (no GFP + tumour cells), 1 (sparse GFP + tumour cells on one lymph node), 2 (sparse GFP + tumour cells on both lymph nodes, or strong GFP + tumour cell patches on only one lymph node), 3 (sparse GFP + tumour cells on one lymph node and strong GFP + tumour cell patches on the other lymph node), or 4 (strong GFP + tumour cell patches on the both lymph nodes). Spontaneous lung micrometastasis was quantified by counting tumour cell clusters with more than ten GFP + tumour cells in each cluster. Immunohistochemistry, immunofluorescence, and western blot. Tissues were fixed in 10% formalin overnight and embedded in paraffin. Immunohistochemical and immunofluorescence staining was performed as previously described 11, 14 . Immunohistochemical slides were scanned with a Pannoramic Digital Slide Scanner (3DHISTECH) and images were cropped from virtual slides in Pannoramic Viewer. Immunofluorescence slides were imaged with a Nikon A1R Confocal Laser Microscope and quantified with ImageJ. Primary antibodies used included CK5 (Covance, PRB-160P), CK8 (Covance, MMS-162P), Ki67 (Fisher, RM-9106-S1), cleaved caspase 3 (Cell Signaling Technology, 9661), Gr-1 (BioLegend, 108401) , phospho-S6 (Cell Signaling Technology, 4858). For western blot analysis, cells or fresh tissues were lysed on ice using RIPA buffer (Boston BioProducts) supplemented with protease and phosphatase inhibitors (Roche). Western blot procedure was performed as previously described 11, 14 35 (calculation based on average body mass of 25 g and daily food intake of 5 g per day, with online calculator at www.researchdiets.com/resource-center-page/ diet-dose-calculator). To induce castration-resistant PCa, mice with prostate tumour confirmed by MRI were surgically castrated and started on an Enzamixed diet for 3 weeks before being moved back to regular chow and treated with therapeutic drugs. For in vivo pharmacological inhibition, BEZ235 (Selleck Chemicals, S1009), cabozantinib (Selleck Chemicals, S1119), dasatinib (Selleck Chemicals, S1021), PI-3065 (MedKoo, 407192), and GSK2636771 (MedKoo, 205844) were orally administered at daily doses of 45 mg per kg, 30 mg per kg, 30 mg per kg, 50 mg per kg, and 30 mg per kg, respectively, daily on a Monday-Friday schedule. SX-682 (Syntrix Biosystems) was orally administered twice a day at 50 mg per kg actual dose on a Monday-Friday schedule. Similar drug dosing methods were described previously 27, 28, [36] [37] [38] . The doses we used for cabozantinib and BEZ235 are clinically relevant: for cabozantinib, to convert the mouse dose into human dose, we calculated 30 mg per kg × (1/12.3) = 2.4 mg per kg daily in human (the conversion factor 12.3 can be found in FDA guidance at http://www. fda.gov/downloads/Drugs/.../Guidances/UCM078932 and in ref. 39) . Given a typical human weight of 60 kg, the clinical dose range of 60 mg daily (PCa, renal cell carcinoma) to 140 mg daily (medullary thyroid cancer) converts to a human dose range of 1-2.3 mg per kg daily. Therefore, our cabozantinib dose in mice approximates the approved dose for treating medullary thyroid cancer, and is 1.4 times higher than used in COMET-1 and COMET-2 phase III trials of advanced PCa. For BEZ235, previous studies showed that while 300 or 400 mg twice daily 40 showed significant toxicity in patients, 200 mg twice daily displayed higher tolerability 41 . The dose we used in the mice study, 45 mg per kg daily, is approximately equivalent to 225 mg daily in humans, and thus is within range of tolerable clinical doses. For ICB and Gr1-neutralizing antibody treatment, anti-PD1 (clone RMP1-14, BioXcell, BE0146), anti-CTLA4 (clone 9H10, BioXcell, BE0131), or anti-Gr1 (clone RB6-8C5, BioXcell, BE0075) antibodies (or their respective isotype IgG controls) were intraperitoneally administered at 200 μ g per injection three times per week. The duration of drug treatment was typically 4 weeks before endpoint analysis. CyTOF of human specimens and mouse tumours. CyTOF analysis of mouse prostate tumours with data analysed in FlowJo (Tree Star) followed our previous methods 11 . Human prostate fine-needle aspirate specimens were acquired under approved institutional review board Protocol PA14-0420 at MD Anderson Cancer Center. Informed consent was obtained from all subjects. Prostate tumour single cells were isolated using a Human Tumour Dissociation kit (Miltenyl Biotec, 130-095-929). All isolated cells were depleted of erythrocytes by hypotonic lysis. Cells were blocked with FcR Blocking Reagent (Miltenyl Biotec, 130-059-901) for 10 min and incubated with CyTOF antibody mix for 30 min at room temperature. Cells were washed once and incubated with Cell-ID Cisplatin (Fluidigm, 201064) at 2.5 μ M for 2.5 min for viability staining. Cells were fixed with MaxPar Fix and Perm Buffer containing Cell-ID Intercalator-Ir (Fluidigm, 201192A) at 0.125 μ M and 4 °C overnight to stain the nuclei. The samples were analysed with a CyTOF instrument (Fluidigm) in the Flow Cytometry and Cellular Imaging Core Facility at MD Anderson Cancer Center. Data were analysed with FlowJo (Tree Star) and SPADE software 42 . Cell isolation and in vitro survival and migration assay. Over 95% of all CD11b + Gr1 + myeloid cells in established naive or castration-resistant prostate tumours in CPPSML mice are granulocytic (Ly-6G + Ly-6C Low ), similar to the level in the PB-Cre + Pten L/L Smad4 L/L model that we recently reported 11 . Gr-MDSCs were isolated from prostate tumours by first enriching for lymphocytes using Lympholyte-M Cell Separation Media (Cederlane, CL5031) followed by MACSbased isolation using a Mouse MDSC Isolation Kit (Miltenyi Biotec, 130-094-538) and plated in RPMI1640 supplemented with 10% FBS and antibiotics. From the same mice, CD8 + T cells were isolated from the spleen using a Mouse CD8a + T Cell Isolation Kit (Miltenyi Biotec, 130-104-075). MDSCs and CD8 + T cells were cultured as described 20 . GFP + PCa cells were isolated from the prostate tumours by fluorescence-activated cell sorting with a BD FACSAria III Cell Sorter, and cultured in complete DMEM supplemented with 10% FBS and antibiotics. The purity of Gr-MDSCs (CD11b + Gr1 + Ly6G + Ly6C low F4/80 − ), CD8 + T-cell (CD3 + CD8 + ), and PCa-cell (GFP + Tomato − CD45 − ) populations was greater than 90%, as determined by flow cytometry. A survival assay was performed on 96-well plates with Cell Proliferation Reagent WST-1 (Sigma-Aldrich, 11644807001) as described 20 . Serially diluted drugs (BEZ, Cabo, Dasa) were added to the culture to construct dose-response curves and the IC 50 value was calculated with GraphPad Prism 6 software. For the migration assay, Gr-MDSCs isolated from prostate tumours using MACS technology were added to the upper chamber of a 24-well trans-well system (BD Falcon). MDSC short-term culture medium (RPMI1640 supplemented with 10% FBS) with the indicated concentrations of recombinant mouse IL-1α (BioLegend, 575002), IL-1β (BioLegend, 575102), IL-1ra (VWR, 10006-448), or mouse IL-1ra neutralizing antibody (R&D Systems, AF-480-NA) was added to the bottom chamber. Cells were allowed to migrate to the bottom well for 6 h at 37 °C with 5% CO 2 . Migrated cells were fixed and stained with crystal violet for quantification. T-cell suppression assay and quantification of cytokine production. A T-cell suppression assay was performed as we previously described 11 using equal numbers of MACS-sorted intratumoural Gr-MDSCs and CFSE-(Invitrogen) labelled MACS-sorted CD8 + or CD4 + T cells from spleen of wild-type C57BL/6 mice (The Jackson Laboratory, 000664). To assess the effect of drugs (BEZ, Cabo, Dasa) on the proliferation of T cells, drugs at different concentrations were added to anti-CD3/anti-CD28-stimulated CFSE-labelled and MACS-sorted CD8 + or CD4 + T cells from spleen of wild-type C57BL/6 mice at time zero. CFSE intensity was quantified 72 h later with peaks identified by a BD LSRFortessa Cell Analyzer. CFSE peaks indicated the division times. Division times 0, 1-2, and ≥ 3 were defined as no proliferation, moderate proliferation, and high proliferation, respectively. Viable CD4 + or CD8 + T cells (viability defined as negative DAPI (4′ ,6-diamidino-2-phenylindole) stain) falling in each category were quantified as the percentage of total live CD4 + or CD8 + T cells, respectively. The supernatant medium was used to quantify IFNγ and IL-2 production by ELISA following the manufacturer's manual (BioLegend, 430804 and 431004). Antibody array. Mouse prostate tumours treated with defined agents were processed as instructed by the manufacturer's protocol, and an equal amount (micrograms) of lysate was used to quantify phospho-RTK proteins with a Proteome Profiler Mouse Phospho-RTK Array Kit (R&D Systems, ARY014) or a Proteome Profiler Mouse XL Cytokine Array Kit (R&D Systems, ARY028). Medium conditioned by CPPSML PCa cell lines was analysed with a Proteome Profiler Mouse Cytokine Array Kit -Panel A (R&D Systems, ARY006). Quantification of the spot intensity in the arrays was conducted with background subtraction in ImageJ. Transfection of recombinant proteins. MACS-sorted MDSCs isolated from mouse prostate tumours were co-transfected with recombinant active ERK2 (R&D Systems, 1230-KS-010) and p70S6K (R&D Systems, 896-KS-010) following the manufacturer's protocol of Chariot Protein Delivery Reagent (Active Motif, 30025). The transfection efficiency was verified to be over 80% in separate wells of MDSCs transfected with β -galactosidase and stained with a Beta-Galactosidase Staining Kit (Clontech, 631780). The effect of co-transfection on the resistance of MDSCs to drug treatment was evaluated 12 h after transfection with Cell Proliferation Reagent WST-1 (Sigma-Aldrich, 11644807001). Treatment of MDSCs with PCa-cell conditioned medium. CPPSML PCa cell lines established and grown in complete DMEM supplemented with 10% FBS were cultured to 90% confluence and renewed with fresh medium followed by medium collection (0.45 μ m filtered) 12 h later. The homozygous deletion of Pten, p53, and Smad4 was confirmed with genotyping, and all cell lines were confirmed free of mycoplasma with a MycoAlert Mycoplasma Detection Kit (Lonza). When the cells were required to be pre-treated with Cabo or BEZ, the renewed medium was supplemented with the drugs at indicated concentration and added to cells. Twelve hours later, conditioned medium was collected with any floating cells removed by 0.45 μ m filter, and subsequently concentrated 50-fold with an Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-3 membrane (Millipore, UFC900324) to deplete small compounds but retain proteins larger than 3 kDa (including most cytokines). Such concentrated medium was diluted back to onefold with complete DMEM. The conditioned medium was used within 12 h of collection to culture MACS-sorted MDSCs isolated from mouse prostate tumours. Unconditioned complete DMEM supplemented with 10% FBS was used as negative control. To test whether supplementing drug pre-treated conditioned medium with specific cytokines could reverse the effect on MDSCs, the ten cytokines (all from BioLegend) were added individually at 100 ng ml −1 . Quantitative RT-PCR. RNA was isolated by RNeasy Kit (Qiagen) and reversed transcribed using a Superscript III cDNA synthesis Kit (Life Technology). Quantitative PCR was performed using a SYBR-GreenER Kit (Life Technology). The following primers were used: Arg1_F, CTCCAAGCCAAAGTCCTTAGAG; Arg1_R, AGGAGCTGTCATTAGGGACATC; Ncf1_F, ACACCTTCATTCGCCATATTGC; Ncf1_R, TCGGTGAATTTTCTGTAGACCAC; Ncf4_F, GTGAACTCGGCCT GGATCTG; Ncf4_R, AAGCTGCTCAAAGTCGCTCT; Cybb_F, CCTCTAC CAAAACCATTCGGAG; Cybb_R, CTGTCCACGTACAATTCGTTCA; internal control Gapdh_F, AGGTCGGTGTGAACGGATTTG; Gapdh_R, TGTAGACCATGTAGTTGAGGTCA. Preparation of SX-682. SX-682 synthesis was performed at Syntrix Biosystems and is described in the patent US 8969365 B2 (publication date 3 March 2015).
LETTER RESEARCH
General chemicals, reagents, and precursors for synthesis were purchased from Sigma-Aldrich (Milwaukee, Wisconsin, USA), Boron Molecular (Research Triangle Park, North Carolina, USA), and Frontier Scientific (Logan, Utah, USA). Solvents were purchased from either VWR International (West Chester, Pennsylvania, USA) or Sigma-Aldrich (Milwaukee, Wisconsin, USA) and used without further purification. The synthesis steps are described below as illustrated in Extended Data Fig. 7g .
2-Chloro-pyrimidine-5-carboxylic acid (1) (3.16 g, 20 mmol, Frontier Scientific, Logan, Utah, USA) was suspended in dichloromethane (40 ml) , and oxalyl chloride (3.30 g, 26 mmol) was added, followed by DMF (three drops) as catalyst. The reaction started to vigorously evolve gas. The reaction was heated to reflux for 1 h, and then allowed to cool to room temperature. 4-Fluoroaniline (2.44 g, 2.2 mmol) was added, vigorous bubbling was seen again, and the reaction mixture warmed up considerably. Triethylamine (4.05 g, 40 mmol) was added, and a flocculent precipitate immediately formed. The reaction mixture was heated to reflux once again for another hour, removed from heat, and stirred at room temperature for 18 h under nitrogen. The reaction was diluted with EtOAc (100 ml), and the organic layer In a round-bottomed flask, the intermediate 2-chloro-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)-amide (2.52 g, 10.0 mmol) and anhydrous sodium hydrogen sulfide (1.22 g, 21.8 mmol) were suspended in anhydrous DMF (20 ml). The suspension was stirred at room temperature, and the reaction mixture turned a deep green colour. After 1 h, the reaction mixture was partitioned between EtOAc and H 2 O, and transferred to a separatory funnel. After the layers were separated, the organic layer was washed twice with a 2:1 mixture of H 2 O and 5% aqueous NaHCO 3 . The combined aqueous layers were acidified with 1 N HCl precipitating a yellow solid. The suspension was left to stand at room temperature for 2 h, and then the precipitate was collected by vacuum filtration, and rinsed with water. The yellow solid was dried overnight in a vacuum desiccator to yield 2.3 g (92%) of the thiopyrimidinamide intermediate 2. 1 (20 ml) . Sonication was used to dissolve the compounds. To the reaction flask triethylamine (2.8 ml, 20.1 mmol, Sigma Aldrich, Milwaukee, Wisconsin, USA) was added and a precipitate (triethylamine-HBr) immediately formed. The reaction was layered with nitrogen gas and left to stand at room temperature for 3.75 h. The reaction was poured into H 2 O (500 ml) and layered with EtOAc. The biphasic solution was transferred to a separatory funnel and diluted further with EtOAc and brine. The layers were separated, and the aqueous layer was extracted twice more with EtOAc. The combined organic layers were dried over Na 2 SO 4 , gravity filtered, and dried by rotary evaporation to yield 5.7 g (98%) of an oil, 2-[2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-5trifluoromethoxy-benzylsulfanyl]-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)amide (3). 1 The pinacolyl boronate ester was deprotected via hydrolysis of the intermediate trifluoroborate 43 . Compound 3 (5.66 g, 10.3 mmol, 1 eq.) was dissolved in methanol (100 ml). The reaction vessel was charged with 4.5 M aqueous potassium hydrogen fluoride (11.5 ml, 5 eq.) and the resulting solution was stirred for 1 h. The methanol was removed by rotary evaporation at room temperature and the resulting mixture of yellow and off-white solids was suspended in acetone. The suspension was gravity filtered to remove the insoluble salts, and the resulting clear yellow solution was added via pipette to a flask of H 2 O (2 l) and placed in the refrigerator. After cooling for about 1.5 h, the resulting off-white precipitate was collected by vacuum filtration, rinsing with water. The funnel was dried overnight in a vacuum desiccator to afford 3.87 g (80%) of 2-(2-boronic acid-5trifluoromethoxy-benzylsulfanyl)-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)amide (4) 3.20) , N (8.99, 8.99), S (6.86, 6.73). Statistical analysis. Data are presented as mean ± s.d. unless indicated otherwise. Sample size was chosen to ensure 80% power to detect significant effect size on the basis of our recent publications using the transgenic PCa mouse models and thereof derived primary tumour and myeloid cells 11, 13, 14 . A Student's t-test assuming two-tailed distributions or a non-parametric Mann-Whitney U-test was used to calculate statistical significance between groups (no assumption was made that variance was similar between the groups being statistically compared). P < 0.05 was considered statistically significant. Data availability statement. Source Data for the main and Extended Data Figures are provided in the online version of this paper. All other data are available from the corresponding authors upon reasonable request.
Extended Data Figure 1 | Chimaeric modelling as an efficient approach to generating spontaneous metastatic PCa. a, Comparison of probability of obtaining PCa-bearing males with CPPSML genotype in a litter, through breeding or chimaeric modelling. In chimaeric modelling, > 75% coat colour contributed by injected mES cells (mESC in the figure) is defined as positivity for chimaera. b, c, Predicted and experimental results for PCR-RFLP genotyping of the H2 locus from several mouse strains and two mES cell lines (JM8 is a standard mES cell line derived from C57BL/6 strain as control; Ep61 is also known as JH61). Red asterisk in b and yellow highlight wells in c indicate that the H2 haplotyte for JH61 is H2 b , the same as the C57BL/6 strain. d, SSLP marker analysis of the region on chromosome 17 flanking the H2 complex locus (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) , showing that JH61 has 100% C57BL/6 background in the H2 locus, identical to the standard C57BL/6 mES cell line JM8. e, Experimental steps for generating the CPPSML chimaeras. f, Fluorescence images of prostate, draining lymph node (LN), and lung from a representative chimaera at 3 months old. GFP + signals indicate the presence of metastasis to lymph nodes and disseminated tumour cells and micrometastasis in lung. Scale bars: prostate, 5 mm; lymph node and lung, 1 mm. g, Fluorescence microscopy and H&E image of snap-frozen prostate tumour from chimaera showing that the GFP + area corresponds to adenocarcinoma and the GFP − area corresponds to normal host cells. Scale bar, 500 μ m. In this Letter, owing to an error during the production process, the x-axis label 'BEZ + ICB' appeared twice in each of the graphs in Fig. 1d-f , and the 'Cabo + ICB' label was missing. In each graph, the first 'BEZ + ICB' label should have read 'Cabo + ICB' . The original Letter has been corrected online.
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